Objective: This study tested the hypothesis that minimally invasive microneedles cause less pain during injection of lidocaine, but induce local anesthesia in humans with the same rapid onset and efficacy as intradermal lidocaine injection using hypodermic needles.
A n ideal local anesthesia system for use in ambulatory clinical environments should be effective, have rapid onset, cause minimal pain, be fast and easy to load and administer with minimal user training, be portable without bulky equipment, and be cost effective. 1 Although several methods of inducing local anesthesia exist, each of them comes with limitations.
Hypodermic needle injection is the most common means of administering local anesthesia and allows for rapid onset with good efficacy. Hypodermic needles, however, can cause pain, anxiety, and distress leading to poor patient adherence, especially among children 2, 3 and require administration by experienced medical personnel. Topical anesthetic creams and gels provide a painless and simple means of administering anesthesia; however, these techniques rely on passive diffusion across the skin's outermost layer (stratum corneum) which leads to slow onset times ranging from 30 minutes to 1.5 hours. 1, 3 This delayed onset is a principal barrier to widespread use of topical anesthetics for venous access procedures.
More recently, several needle-free, active drug delivery devices, such as iontophoresis, ultrasound, jet injection, and laser/thermal ablation-based systems have been developed to administer local anesthetics. However, several such commercialized devices have had poor market acceptance and have been discontinued over the past few years (Anesiva Annual Report, 2008; Vyteris Annual Report, 2008) .
We propose the use of micron-dimension needles called microneedles to administer local anesthetics in a simple and minimally invasive manner while allowing for rapid onset of analgesic action. Microneedles can be fabricated as solid or hollow structures that are long enough to deliver drug by breaching the stratum corneum, but are short enough to avoid stimulating nerve endings in the dermis. 4 Hollow microneedles administer drugs by means of active injection and can be used to deliver large volumes to the skin. Studies have demonstrated the local and systemic effects of hollow microneedle-based injection using methyl nicotinate 5 and insulin 6 in humans. Small (1.5 mm long) hypodermic needles developed by Becton Dickinson have been used for influenza vaccination in elderly humans resulting in a stronger immune response than intramuscular injection. 7 Further, arrays of hollow microneedles have also demonstrated influenza vaccine injection in humans. 8 With respect to pain, previous studies have demonstrated that skin insertion of solid piercing structures with similar geometries as hollow microneedles used in this study was significantly less painful than 25-gauge and 26-gauge hypodermic needles. [9] [10] [11] Further, short hypodermic needles have also been found to be significantly less painful than 26-gauge needles inserted intradermally. 12 Guided by this previous literature, this study reports for the first time (1) the pain associated with hollow microneedle injection, (2) microneedle-based delivery for a local therapeutic drug response, and (3) the efficacy of lidocaine administration using microneedles to cause local anesthesia in human participants.
MATERIALS AND METHODS

Participants
Fifteen healthy human participants (11 male, 4 female; age, 22 to 56 y) were recruited. Participants having diseased or abnormal skin, known diseases affecting nerve function or perception of pain, allergies to lidocaine, and veins on the dorsum of their hand without easy access were excluded. The study was approved by the Emory University's Institutional Review Board and carried out in accordance with the Declaration of Helsinki protocol. All participants provided informed consent before participation.
End points
The following end points were measured: (1) pain associated with microneedle and hypodermic needle-based lidocaine injection; (2) area and (3) depth of skin numbness at 0, 7.5, and 15 minutes after injection; (4) efficacy based on pain associated with placement of an intravenous catheter immediately after lidocaine injection; and (5) preferred treatment method among microneedle and hypodermic needle injection.
Lidocaine
A preservative-free 2% lidocaine hydrochloride injectable solution (Hospira, Lake Forest, IL) was used for all injections.
Microneedle Fabrication and Injection
Hollow borosilicate-glass microneedles ( Fig. 1 ) with a 30-degree bevel angle and tip radii of 60 to 80 mm were fabricated as described previously. 6 Microneedles were inserted at a 90-degree angle into skin to a depth of 500 mm using a custom rotary drilling device with ±10 mm precision, although the insertion depth into the skin was probably an order of magnitude less accurate because of the variable deformation of the skin during microneedle insertion. 13 The microneedle was connected to a 3 mL syringe and a syringe pump (NE-1000, New Era Systems, Farmingdale, NY) which controlled lidocaine flow rate at 300 mL/min. 6 Microneedles were removed from the skin approximately 5 seconds after injection.
Hypodermic Needle Injection
A 26-gauge 3/8" intradermal bevel needle connected to a 1 mL syringe was used as the positive control. The needle was inserted at an angle almost parallel to the skin surface into the intradermal space by experienced anesthesiology personnel and lidocaine was injected within 3 to 5 seconds.
Study Design
This study was a randomized, within participants, controlled, single-blinded design and was carried out in 2 phases. One phase was performed on the forearm while the other on the dorsum of the hand. The forearm phase assessed pain associated with microneedle-based injection and determined the efficacy of delivery by measuring area and depth of numbness. The dorsum of the hand phase further assessed pain associated with microneedle-based injection and determined efficacy by measuring pain during intravenous catheter placement. All participants received treatments with both devices on their forearms and the dorsum of their hands and each participant served as his/ her own control. The sequence of these 2 phases (forearm or dorsum) was randomized among participants. Within each phase, the treatment sequence (microneedle or hypodermic needle) and the forearm/hand (left or right) were also randomized. Participants were blinded throughout the study by placing their arms under a curtain barrier.
Forearm Protocol
The volar forearm insertion site was identified and marked 7 cm from the midpoint of the antecubital fossa. The site was then wiped with isopropanol swabs followed by injection of 200 mL of lidocaine using a microneedle or hypodermic needle as per the randomization schedule. The participant rated the pain associated with injection using a 100-mm visual analog scale (VAS) and the score was recorded by a blinded observer. The participant was then asked if he/she considered the procedure to be painful. The area of numbness was measured using a pin-prick test by gently tapping a 25-gauge 3.5" spinal needle (Becton Dickinson, Franklin Lakes, NJ) on the skin starting from the insertion point and extending radially outward in 4 directions until the participant felt a sensation. The depth of numbness was measured by inserting a 26-gauge 3/8" hypodermic needle up to a maximum of 9.5 mm into the skin at the injection site until the participant indicated that he/she felt sensation.
The procedure took approximately 2 minutes to complete and was performed immediately after lidocaine injection (T=0) and again at 7.5 and 15 minutes after injection. This procedure was then repeated on the opposite forearm using the other injection method. At the end of both treatment procedures, participants were asked to rank their preference between the microneedle and hypodermic needle injection procedures.
Dorsum of Hand Protocol
A site near a vein accessible for venipuncture was identified and wiped with isopropanol swabs. Lidocaine (100 mL) was then injected using a microneedle or hypodermic needle to generate a skin wheal. The participant rated the pain associated with injection using the VAS scale and indicated if the procedure was painful. A 22-gauge intravenous catheter (Optiva, Smiths Medical, Carlsbad, CA) was then inserted through the wheal into the vein until a small amount of blood appeared in the hub, upon which the intravenous catheter was immediately removed. The site was wiped with an isopropanol swab and covered with an adhesive bandage. The participant then rated the pain of inserting the intravenous catheter and indicated if the procedure was painful. The procedure was repeated on the opposite hand using the other injection method. At the end of both treatments, the participant was asked to indicate the preferred treatment method.
Local Skin Reaction
Immediately after lidocaine injection and 1 hour post injection, treatment sites were visually examined for any evidence of skin irritation.
Statistical Analysis
All data are expressed as mean±standard deviation. VAS pain scores for hypodermic and microneedle-based lidocaine injection and venous cannulation pain scores were compared using paired, 2-tailed Student's t test. In all cases, P<0.05 was the minimum value considered acceptable for rejection of the null hypothesis. Differences in the radii of numbness (top, bottom, left, and right) for the 2 treatment methods over all 3 time points were compared using a repeated measures 3-way analysis of variance (ANOVA). We used a repeated measures 2-way ANOVA to compare the total area and depth measurements for the 2 devices over the 3 time points. All comparisons were performed using NCSS (Kaysville, UT) and Minitab (State College, PA) software. Data from incomplete injections due to leakage from either injection devices were excluded from the analyses.
RESULTS
Study Population
Fifteen healthy individuals gave informed consent and participated in this study. Of the enrolled participants, data from 13 (87%) were included in the forearm phase. The other 2 participants experienced incomplete lidocaine delivery during the injection procedure. Data from 11 (73%) participants were analyzed for the dorsum of the hand phase for the same reason.
Assessment of Pain
To test the hypothesis that microneedle-based injection is less painful than hypodermic needle-based injection, VAS pain scores were measured for the 2 injection methods (Fig. 2, Table 1 ). Microneedles were significantly less painful than hypodermic needles for both forearm (Student's t test; P=0.002) and dorsum of the hand (P=0.013) injection procedures. On average, the hypodermic needle received a VAS score much larger than the microneedle for both forearm injections and dorsum injections. Further, 92% of forearm protocol participants reported the microneedle procedure to be painless compared with only 25% for the hypodermic needle. For the dorsum of the hand protocol, 82% of participants reported the microneedle procedure to be painless, whereas only 27% thought the hypodermic needle caused no pain. Although the sample size in this study was small, post hoc power analysis (G*Power3, Kiel, Germany) revealed that there was a Z80% power of detecting a statistically significant difference, should it exist, for both phases using the chosen experimental design.
Area of Numbness
To determine whether microneedle injection was as effective as hypodermic needles in inducing anesthesia over a clinically relevant area, the area of numbness was measured using the pin-prick protocol described above for the forearm at T=0, 7.5, and 15 minutes after delivery. As seen in Figures 3A to C, uniform anesthesia was achieved in all directions, creating a circular area of numbness for both delivery methods. There were no significant differences in the anesthetized regions along any of the 4 axes of measurement or the total areas of numbness between the 2 treatment methods (repeated measures 3-way ANOVA; P>0.05) for all time points. The average areas over the 15 minutes measurement period were 4.0±1.8 cm 2 and 4.3±1.9 cm 2 for the microneedle and hypodermic needle treated forearm sites, respectively (Fig. 3D ). There were no significant differences (repeated measures 2-way ANOVA; P>0.05) among the anesthetized areas for both treatment methods at any time point over the study period.
Depth of Numbness
To test the depth of anesthesia, a 26-gauge, 9.5-mm long hypodermic needle was inserted into the forearm skin at the site of lidocaine injection until participants indicated they felt a sensation (Fig. 3E ). There were no significant differences in the depth of anesthesia for the 2 injection methods across all time points (repeated measures 2-way ANOVA; P>0.05).
Efficacy of Injection Method Based on Venous Cannulation
To test the efficacy of microneedle-based lidocaine administration for use in clinical applications further, an intravenous catheter was inserted into a vein on the dorsum of the hand immediately after lidocaine injection near the vein (Fig. 4, Table 1 ). Microneedles were as effective as hypodermic needles in administering rapid dermal anesthesia for venous cannulation, as there was no significant difference between the intravenous insertion pain scores for the 2 treatment methods (Student's t test; P=0.130). Notably, 82% of the participants considered the intravenous insertion postmicroneedle treatment to be painless and 91% considered cannulation after hypodermic needle treatment to be painless.
Onset of Anesthesia
As seen from Figure 3 , the area and depth of numbness were the same at T=0 minutes for both the microneedle and hypodermic needle injections. Further, there were no significant differences in the intravenous catheter placement pain scores for the 2 treatment methods immediately after lidocaine injection ( Table 1) .
Preference of Treatment Method
In an attempt to determine whether microneedles would be clinically accepted by patients, at the end of each protocol (forearm and dorsum of the hand), participants were asked which treatment method they would prefer (first vs. second procedure) to receive in a clinical setting. For the forearm injection protocol, 78% of participants reported they would prefer microneedles. For the dorsum protocol, treatment preference was assessed for the overall procedure (ie, lidocaine injection and intravenous catheter insertion) with 82% of participants reporting they would prefer microneedle injection. Thus, even though the participants were blinded to the treatments, a large majority of participants preferred microneedle-based lidocaine injection over hypodermic needles. Preference rates could be still higher during nonblinded procedures in which the fear associated with seeing needles is reduced through the use of microneedles.
Local Skin Reaction and Adverse Events
To study the effect of microneedles on skin irritation, the treatment sites were visually examined for local skin reactions. Immediately after injection, a distinct raised skin wheal confirming intradermal delivery was observed at the treatment site (Figs. 5) . In participants with light skin, very mild erythema and slight skin blanching were observed. Both the skin wheal and erythema were either reduced or disappeared within 1 hours of treatment. Within 24 hours, participants self-reported that there were no signs of erythema or edema.
Corresponding treatment with hypodermic needles resulted in a similar raised skin wheal that was either reduced or had disappeared within 1 hour. In contrast, hypodermic needle insertions led to the presence of a drop of blood at the injection site immediately after treatment, which was never seen after microneedle injections. Punctate redness at the hypodermic needle insertion point also often appeared 1 hour after treatment. Participants reported no wheal after 24 hours, although in some cases, participants still observed punctate redness at the hypodermic needle injection site. There were no adverse events observed or reported during or after the study. Overall, skin responses to microneedle and hypodermic needle injection were similar, although hypodermic needle caused minor bleeding and seemed to cause more lasting local trauma to the skin.
DISCUSSION
This study supports the hypothesis that minimally invasive microneedles cause less pain during injection of lidocaine, but induce local anesthesia in humans with the same rapid onset and efficacy as intradermal injections using hypodermic needles. Microneedles were less painful than hypodermic needles for both the forearm and dorsum protocols as indicated by the injection VAS pain scores. Previous studies have shown that the minimum difference in VAS scores for results to be considered clinically significant is between 9 and 13 mm. 14,15 Therefore, our results with differences of 16.4 mm and 17.2 mm between the average pain scores for the 2 treatment methods for the forearm and hand-dorsum procedures were also significant from a clinical standpoint.
We hypothesize that the reduced pain associated with the microneedle is due to its small size and shallow insertion depth into the skin. However, another factor could be the slower injection rate when using microneedles. Although 100 to 200 mL was injected using the hypodermic needle in 3 to 5 seconds, injection of the same volumes using a microneedle required 20 to 40 seconds at the flow rate of 300 mL/min used in this study. We believe, however, that the slower infusion rate was only a secondary factor, because separate studies injecting insulin 6 and sterile saline 16 showed that increasing flow rate approximately 3-fold to 1 mL/min did not significantly affect pain scores.
Both microneedle and hypodermic needle-based lidocaine injections induced anesthesia immediately after injection, indicating rapid onset time as seen from the comparable area and depth of numbness at T=0 and from the comparable VAS scores for intravenous catheter placement. The results of this study also indicated no significant differences in the depth of anesthesia induced by the 2 devices. This depth of anesthesia is almost 2 times greater than that induced by EMLA (5 mm) 17 and similar to depths induced by iontophoresis, which are 6 to 10 mm. 18 Thus, by inserting a microneedle 500 mm deep into skin, we were able to generate numbness to a depth almost 20 times the needle length.
An advantage of hypodermic needle injection is that it is fast, requiring just 3 to 5 seconds to inject 100 to 200 mL.
Microneedle injection required 20 to 40 seconds to inject 100 to 200 mL in this study, which used a flow rate of 300 mL/min. The flow rate can be increased, for example to 1 mL/min as we did in our previous study of insulin delivery, 6 and thereby reduce injection time to 6 to 12 seconds. Thus, microneedle injection times are not much longer than hypodermic needle injections, which is important to acceptance in busy clinical environments. In contrast, noninvasive lidocaine delivery methods, such as iontophoresis, ultrasound, and jet injectors, have application and onset times varying between 2 to 15 minutes, whereas topical creams and gels have onset times that can exceed 1 hour. 3 With respect to cost, microneedles can be manufactured at very low cost expected to be just a few cents each in mass production. 19 Therefore, microneedles are likely to be cost competitive with other disposable/consumable systems, such as hypodermic needles (which also cost a few cents) and topical anesthetics, and significantly cheaper than more complex technologies such as iontophoresis, ultrasound, and jet There was no significant difference between the pain scores for the microneedle and hypodermic needle, indicating the anesthetic effect was similar for both injection procedures.
injection systems, which can cost hundreds to thousands of dollars. 20 Thus, microneedles seem to be a cost-effective solution for reducing time to anesthesia onset in a minimally invasive and significantly less painful manner.
The potential medical significance of this study is that microneedles can provide a less painful yet efficacious alternative to current local anesthesia administration systems. The ability of microneedles to induce significantly less painful and rapid anesthesia before intravenous cannulation as shown in this study can reduce pain associated with venipuncture and intravenous cannulation. This impact can be more significant among children who consider these 2 procedures to be the most common sources of pain in the hospital and the second most common cause of worst pain during hospitalization (second only to the patient's underlying disease). 21, 22 Further, the small size of microneedles makes the needle visually less apparent and may well be a suitable alternative to hypodermic needles for patients with needle phobia. Moreover, commercially manufactured microneedles would require less user training than hypodermic needles as their short depth will ensure reliable intradermal needle insertion as opposed to the Mantoux technique that requires training to achieve reliable intradermal needle placement. 23 In addition, the rapid anesthesia onset makes microneedles attractive for use in busy clinical settings.
A limitation of this study is that the microneedles and microneedle-insertion device used in this pilot study were laboratory prototypes that are still under development. Glass microneedles were used in this study, because they were easy to fabricate. The experimental nature of the prototype device also led to leakage of lidocaine during some injections resulting in incomplete injections. To address these limitations, we have recently used methods suitable for mass production to fabricate metal microneedles out of medical-grade stainless steel that were mounted on a conventional luer lock, and demonstrated reliable intradermal injection using these needles (data not shown).
CONCLUSIONS
This study demonstrates for the first time that minimally invasive microneedles cause less pain during injection while resulting in local anesthesia in humans with the same speed of onset and efficacy as intradermal lidocaine injection using hypodermic needles. Consequently, we believe that microneedles can provide an enabling technology for administering local anesthesia that is acceptable to patients in terms of pain and efficacy, and acceptable to physicians in terms of speed, simplicity, and cost.
